New developments in the treatment of metastatic gastric cancer: Focus on trastuzumab

OncoTargets and Therapy

Volumn 4, Issue , 2011, Pages 21-26

  Rose, Jeffrey S ^a   Bekaii Saab, Tanios S ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Adenocarcinoma; Chemotherapy; Gastric; Gastroesophageal; Trastuzumab

Indexed keywords

CAPECITABINE; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; PACLITAXEL; TRASTUZUMAB;

ADVANCED CANCER; ANEMIA; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CHILL; DIARRHEA; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; FATIGUE; FEVER; HEART LEFT VENTRICLE EJECTION FRACTION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LIGAND BINDING; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PROTEIN FUNCTION; QUALITY OF LIFE; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; STOMACH CANCER; STOMATITIS; THROMBOCYTOPENIA; VOMITING; WEIGHT REDUCTION;

EID: 84859265817     PISSN: 11786930     EISSN: None     Source Type: Journal    
DOI: 10.2147/OTT.S10188     Document Type: Review

References (48)

1. National Cancer Institute. Surveillance epidemiology and end results: cancer of the stomach. URL: http://seer.cancer.gov/statfacts/html/stomach.html. Accessed October 2010.
2. Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006;24(31):4991-4997.
3. Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008;358(1):36-46.
4. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against her-2 for metastatic breast cancer that expresses her-2. N Engl J Med. 2001;344(11):783-792.
5. Gschwind A, Fischer OM, Ullrich A. The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat Rev Cancer. 2004;4(5): 361-370.
6. Baselga J, Swain SM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer. 2009;9(7):463-475.
7. Worthylake R, Opresko LK, Wiley HS. ErbB2 amplification inhibits down-regulation and induces constitutive activation of both ErbB2 and epidermal growth factor receptors. J Biol Chem. 1999;274(13): 8865-8874.
8. Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol. 2008;19(9):1523-1529.
9. Yamamoto T, Ikawa S, Akiyama T, et al. Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor. Nature. 1986;319(6050):230-234.
10. Yonemura Y, Ninomiya I, Yamaguchi A, et al. Evaluation of immunoreactivity for erbB-2 protein as a marker of poor short term prognosis in gastric cancer. Cancer Res. 1991;51(3):1034-1038.
11. Grabsh H, Sivakumar S, Gray S, Gabbert HE, Mulller W. HER2 expression in gastric cancer: rare, heterogeneous and of no prognostic value conclusions from 924 cases of two independent case series. Cell Oncol. 2010;32(1-2):57-65.
12. Hofmann M, Stoss O, Shi D, et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology. 2008;52(7):797-805.
13. Tanner M, Hollmen M, Junttila TT, et al. Amplification of HER2 in gastric carcinoma: associated with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Onc. 2005;16(2):273-278.
14. Bang Y, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2 positive advanced gastric or gastro-esophageal junction cancer (ToGA): a phase 3, open-label, randomized controlled trial. Lancet. 2010;376(9742):687-697.
15. Zhang XL, Yang YS, Xu DP, et al. Comparative study on overexpression of HER2/neu and HER3 in gastric cancer. World J Surg. 2009;33(10): 2112-2118.
16. Matsubara J, Yamada Y, Hirashima Y, et al. Impact of insulin-like growth factor type 1 receptor, epidermal growth factor receptor, and HER2 expressions on outcomes of patients with gastric cancer. Clin Cancer Res. 2008;14(10):3022-3029.
17. Mizutani T, Onda M, Tokunaga A, Yamanaka N, Sugisaki Y. Relationship of C-erbB-2 protein expression and gene amplication to invasion and metastasis in human gastric cancer. Cancer. 1993:72(7):2083-2088.
18. Tateishi M, Toda T, Minamisono Y, Nagasaki S. Clinicopathological significance of c-erbB-2 protein expression in human gastric carcinoma. J Surg Onc. 1992;49(4):209-221.
19. Barros-Silva JD, Leitão D, Afonso L, et al. Association of ERBB2 gene status with histopathological parameters and disease specific survival in gastric carcinoma patients. Br J Cancer. 2009;100(3):488-493.
20. Berx G, Becker KF, Hofler H, van Roy F. Mutations of the human E-cadherin (CDH1) gene. Hum Mutat. 1998;12:226-237.
21. Pedrazzani C, Corso G, Marrelli D, Roviello F. E-cadherin and hereditary diffuse gastric cancer. Surgery. 2007;142(5):645-657.
22. García I, Vizoso F, Martín A, et al. Clinical significance of the epidermal growth factor receptor and HER2 receptor in resectable gastric cancer. Ann Surg Onc. 2003;10(3):234-241.
23. Nakajima M, Sawada H, Yamada Y, et al. The prognostic significance of amplification and overexpression of c-met and c-erbB-2 in human gastric carcinomas. Cancer. 1999;85(9):1894-1902.
24. Uchino S, Tsuda H, Maruyama K, et al. Overexpression of c-erbB-2 protein in gastric cancer. Its correlation with long-term survival of patients. Cancer. 1993;72(11):3179-3184.
25. Matsubara J, Yamada Y, Nakajima TE, et al. Clinical significance of insulin-like growth factor type 1 receptor and epidermal growth factor receptor in patients with advanced gastric cancer. Oncology. 2008; 74(1-2):76-83.
26. Cortes-Funes H, Rivera F, Ales I, et al. Phase II of trastuzumab and cisplatin in patients with advanced gastric cancer with HER2/neu overexpression/ amplification. In: 2007 ASCO annual meeting proceedings part I. J Clin Oncol. 2007:4613.
27. Nicholas G, Cripps C, Au H-J, et al. Early results of a trial of trastuzumab, cisplatin and docetaxel (TCD) for the treatment of metastatic gastric cancer overexpressing HER2. In: ESMO. Ann Oncol. 2006:Abstract 1105.
28. Bekaii-Saab TS, Roda JM, Guenterberg KD, et al. A phase I trial of paclitaxel and trastuzumab in combination with interleukin-12 in patients with HER2/neu-expressing malignancies. Mol Cancer Ther. 2009;8(11):2983-2991.
29. Satoh T, Leon J, Lopez RI, et al. Quality of life results from a phase III trial of trastuzumab plus chemotherapy in first-line HER2-positive advanced gastric and GE junction cancer. In: 2010 ASCO gastrointestinal cancer symposium, Orlando; 2010.
30. Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006;24(31):4991-4997.
31. Ajani JA, Moiseyenko VM, Tjulandin S, et al. Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group. J Clin Oncol. 2007; 25(22):3205-3209.
32. Kornek GV, Raderer M, Scholl B, et al. Effective combination chemotherapy with paclitaxel and cisplatin with or without human granulocyte colony-stimulating factor and/or erythropoietin in patients with advanced gastric cancer. Br J Cancer. 2002;86(12):1858-1863.
33. Esteva FJ, Valero V, Booser D, et al. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol. 2002;20(7):1800-1808.
34. Tedesco KL, Thor AD, Johnson DH, et al. Docetaxel combined with trastuzumab is an active regimen in HER-2 3+ overexpressing and fluorescent in situ hybridization-positive metastatic breast cancer: a multi-institutional phase II trial. J Clin Oncol. 2004;22(6):1071-1077.
35. Marty M, Cognetti F, Maraninchi D, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol. 2005;23(19):4265-4274.
36. Baselga J, Tripathy D, Mendelsohn J, et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol. 1996;14(3):737-744.
37. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody n women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999;17(9):2639-2648.
38. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002;20(3):719-726.
39. Lu CH, Wysqomierski SL, Tseng LM, et al. Preclinical testing of clinically applicable strategies of overcoming trastuzumab resistance by PTEN deficiency. Clin Cancer Res. 2007;13(19):5883-5888.
40. Nahata R, Yuan LX, Zhang B, et al. Insulin-like growth factor-I receptor/ human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res. 2005;65(23):11118-111128.
41. Price-Schiavi SA, Jepson S, Li P, et al. Rat MUC4 (sialomucin complex) reduces binding of anti-ErbB2 antibodies to tumor cell surfaces, a potential mechanism of herceptin resistance. Int J Cancer. 2002;99(6): 783-791.
42. Scaltriti M, Rojo F, Ocana A, et al. Expression of p95HER2 receptor and response to anti-HER2 therapies in breast cancer. J Natl Cancer Inst. 2007;99(8):628-638.
43. Fabi A, Metro G, Ferretti G, et al. Do HER2 positive metastatic breast cancer patients benefit from the use of trastuzumab beyond disease progression? A mono-institutional experience and systemic review of observational studies. Breast. 2008;17(5):499-505.
44. Extra J-M, Antoine E-C, Vincent-Salomon A, et al. Efficacy of trastuzumab in routine clinical practice and after progression for metastatic breast cancer patients: the observational Hermine study. Oncologist. 2010;15(8):799-809.
45. Von Minckwitz G, du Bois A, Schmidt M, et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a German breast group 26/breast international group 03-05 study. J Clin Oncol. 2009;27(12):1999-2006.
46. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2 positive advanced breast cancer. N Eng J Med. 2006;355(26): 2733-2743.
47. Satoh T, Bang Y, Wang J, et al. Interim safety analysis from TYTAN: a phase III Asian study of lapatinib in combination with paclitaxel as secondline therapy in gastric cancer. J Clin Oncol. 2010;28(15s): Abstract 4057.
48. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Eng J Med. 2006;355(1):11-20.